Trial Profile

A phase 3 trial of NE-3107 for the treatment of Parkinson's-disease

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 23 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bezisterim (Primary)
Indications Parkinson's disease
Focus Therapeutic Use

Most Recent Events

16 May 2023 According to a BioVie media release, data from study (NCT05083260 and NCT05227820) presented at the 2023 World Congress on Parkisons Disease and Related Disorders (IAPRD), which will support rationale for this potentially pivotal clinical trial of NE3107 in the treatment of Parkisons Disease
14 Dec 2022 New trial record
07 Dec 2022 According to a BioVie media release, this trial is expected to begin in 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com